A phenylalanine and cyclohexane derivative that acts as a hypoglycemic agent by stimulating the release of insulin from the pancreas. It is used in the treatment of TYPE 2 DIABETES.
Nateglinide has been studied across 12 research domains including 🔥 Metabolic, 🧬 Hormones, 🫁 Liver & Detox, ❤️ Cardiovascular, ⚡ Energy & Fatigue. The primary research focus is 🔥 Metabolic with 84% of studies addressing this area.
The following compounds share molecular targets with Nateglinide, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.
This evidence profile for Nateglinide is generated deterministically from 295 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.
Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.